Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

24.88 -1.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.88

Massimo

25.39

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+55.59% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

914M

3B

Apertura precedente

26.11

Chiusura precedente

24.88

Notizie sul Sentiment di mercato

By Acuity

50%

50%

113 / 339 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 set 2026, 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

25 set 2026, 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

25 set 2026, 23:35 UTC

News

DICK'S Sporting Goods faces two class action lawsuits alleging misleading financial statements, contributing to a modest decline in after-market trading.

25 set 2026, 23:15 UTC

News

Skyworks Solutions Inc. has extended the expiration date for Qorvo's senior notes exchange offers to October 2, 2026, with shares modestly higher in after-market trading.

25 set 2026, 23:05 UTC

News

PepsiCo plans to raise prices on select chips and sodas by late 2026 or early 2027 due to inflation and rising commodity costs, with stock roughly flat in after-market trading.

25 set 2026, 23:05 UTC

News

Vicor Corp raised its third-quarter revenue growth outlook to over 20%, doubling its previous forecast, following a new OEM licensing agreement. Shares advanced in after-market trading.

25 set 2026, 23:05 UTC

News

Moody's affirmed BJ's Wholesale Club's Ba1 rating and revised its outlook to positive, contributing to the asset's modest rise in after-market hours.

25 set 2026, 23:05 UTC

News

Coca-Cola Consolidated Inc appointed Rob Gehring to lead North American operations, effective December 1, as the stock trades lower in after-market hours.

25 set 2026, 23:05 UTC

News

Synopsys Inc is higher in after-market trading following HSBC's new price target of $700, citing AI's potential to enhance revenue capabilities.

25 set 2026, 23:05 UTC

Event
News

Merck & Co. has withdrawn its Biologics License Application for ifinatamab deruxtecan after the FDA indicated insufficient trial data, with shares trading lower in after-market hours.

25 set 2026, 23:05 UTC

News

Monster Beverage shares are modestly lower in after-market trading following CEO Rob Gehring's resignation announcement effective November 30, 2026.

25 set 2026, 23:05 UTC

News

McDonald's Corp plans an $8.5 billion menu overhaul to introduce healthier options, with shares edging higher in after-market trading.

25 set 2026, 23:01 UTC

News

Kodiak Sciences Inc. shares rose in after-market trading as the company announced topline results from its DAYBREAK Phase 3 study will be released on September 28, 2026.

25 set 2026, 23:01 UTC

News

Chevron Corp's shares rose in after-market trading as the company accelerates plans to export gas from Cyprus's Aphrodite field through Egypt's LNG facilities.

25 set 2026, 23:01 UTC

News

Marathon Petroleum's stock is higher in after-market hours as the White House reviews a potential diesel export ban that could impact earnings.

25 set 2026, 23:01 UTC

News

PayPal shares rose in after-market hours amid speculation of a potential all-stock takeover and Deutsche Bank's price target increase to $55 from $50.

25 set 2026, 22:50 UTC

News

S&P Global Ratings downgraded Cable One's credit rating to 'B+' amid increased competition, but the stock has advanced in after-market trading following five consecutive lower sessions.

25 set 2026, 22:45 UTC

News

Viatris Inc is seeing a modest increase in after-market trading after filing a lawsuit against Novo Nordisk over its planned generic Wegovy.

25 set 2026, 22:15 UTC

News

Fox Factory Holding Corp. completed the $225 million sale of Marucci Sports, reducing leverage and interest expenses, leading to higher shares in after-market hours.

25 set 2026, 22:01 UTC

News

S&P Global Ratings upgraded Rithm Capital Corp's credit rating to 'B+' as the firm diversifies revenue, with assets under management rising to $61 billion.

25 set 2026, 21:02 UTC

News

The New York Times Company declared a quarterly dividend of $0.23 per share, while the stock traded modestly lower in after-market hours.

25 set 2026, 21:01 UTC

News

Best Buy Co., Inc. plans to sell debt securities, contributing to a modest decline in after-market trading, with shares lower since Friday's close.

25 set 2026, 20:08 UTC

Social Media
News

Moderna Inc's stock advanced following CEO Stéphane Bancel's comments on focusing on cancer vaccines and recent positive trial results for its melanoma vaccine.

25 set 2026, 20:08 UTC

Social Media
News

Apple shares are advancing as Bernstein maintains a Buy rating with a $370 price target, despite lowering EPS estimates for Q1 to $2.87.

25 set 2026, 20:08 UTC

News

ON Semiconductor Corp shares are sharply higher, driven by the launch of its Embedded Power Platform and strengthened partnerships in automotive and AI sectors.

25 set 2026, 20:08 UTC

News

C3.ai Inc shares declined modestly as options sentiment remained mixed, with a put/call ratio of 0.33 and implied volatility in the lowest 10% of observations.

25 set 2026, 20:08 UTC

News

Snowflake Inc. shares are advancing as the company partners with CrowdStrike to integrate its AI-native Falcon platform into the Snowflake Marketplace.

25 set 2026, 20:08 UTC

Correlated Moves
News

Box Inc shares fell as the resignation of Chief Accounting Officer Eli Berkovitch may have contributed to the stock's ongoing decline, marking six consecutive days lower.

25 set 2026, 20:08 UTC

Social Media
News

Amazon.com Inc. saw moderately bullish options activity, with calls outpacing puts and a put/call ratio of 0.43, amid rising sentiment for October call options.

25 set 2026, 20:08 UTC

News

Aflac shares fell today as Japan Post Holdings sold 12.2k shares, contributing to a price move slightly below Thursday's close.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

55.59% in crescita

Previsioni per 12 mesi

Media 39.333 USD  55.59%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

113 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.